PEA (palmitoylethanolamide) inhibits TLR4

.

.

New insight into the mechanism of action of palmitoylethanolamide was presented in 2013 at EFIC, a Congress for European Pain Specialists:

.
“… Dr Svik Assaw and colleagues from the School of Life Sciences, Medical School, University of Nottingham, United Kingdom presented new exciting data on the mechanism of action of the fatty acid amide N-Palmitoyethanoalamide (PEA) and presented the effects of PEA after activation of toll-like receptors (TLRs) by the inflammatory substance carrageenan.”

.

1. PEA inhibits chemotaxis of monocytes, but not neutrophils (clearly a sign that PEA downregulates chronic inflammation but not acute inflammation)

2. PEA decrease in the carrageenan induced induction of the pro-inflammatory genes IL-1b, CCL4 and NOS2 in the inflamed skin.

3. PEA also blocks CCL4 induced monocyte migration in a chemotaxis assay.

4. PEA clearly modulates the TLR4 mediated inflammatory responses and dose-related inhibits inflammatory evoked TNFa and IL-1b gene expression.”

.

.

~~~~~

The material on this site is for informational purposes only.

It is not a substitute for medical advice,

diagnosis or treatment provided by a qualified health care provider.

~~~~~

Please understand that it is not legal for me

to give medical advice without a consultation.

If you wish an appointment, please telephone my office.

.

For My Home Page, click here:  Welcome to my Weblog on Pain Management!

.

.